To place these findings into a broader clinical context, existing literature indicates that 15–40% of advanced bladder cancers are PD-L1 positive (CPS ≥ 10), depending on the scoring system and cutoff used [64,65]. This evidence concerns the gene CD274 and urinary bladder carcinoma.